Range Impact Announces $550,000 Capital Raise




Range Impact Announces $550,000 Capital Raise

Cleveland, Ohio, Sept. 24, 2025 (GLOBE NEWSWIRE) — Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public impact investing company dedicated to acquiring, reclaiming and repurposing mine sites in Appalachia, announced the closing of a $550,000 capital raise.

Capital Raise

The capital raise was comprised of a $350,000 investment by Tower IV, LLC, an investment vehicle of Joseph E. LoConti, the Company’s largest shareholder, a $100,000 investment by Edward Feighan, the Company’s Chairman of the Board, and a $100,000 investment by Michael Cavanaugh, the Company’s CEO and Board Member.

The investors entered into securities purchase agreements pursuant to which they acquired a total of 3,666,667 shares of Range Impact’s common stock at a price of $0.15 per share.

Michael Cavanaugh, Range Impact’s CEO, stated, “The additional capital investment reflects our largest shareholder’s and board’s continued confidence in our vision and strategy.” Cavanaugh added, “By aligning leadership and capital, we are strengthening our ability to accelerate the reclamation and repurposing of our land assets and unlock long-term value for our shareholders, strategic partners, and the local communities we serve.”

About Range Impact, Inc.

Headquartered in Cleveland, Ohio, Range Impact is a public company (OTC: RNGE) dedicated to improving the health and wellness of people and the planet through a novel and innovative approach to impact investing. Range Impact owns and operates several complementary operating businesses focused on developing long-term solutions to environmental, social, and health challenges, with a particular focus on acquiring, reclaiming and repurposing mine sites and other undervalued land in economically disadvantaged communities throughout Appalachia. Range Impact takes an opportunistic approach to impact investing by leveraging its competitive advantages and looking at solving old problems in new ways. Range Impact seeks to thoughtfully allocate its capital into strategic opportunities that are expected to make a positive impact on the people-planet ecosystem and generate strong investment returns for its shareholders.

Notice Regarding Forward-Looking Statements

This press release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Although we believe that these statements are based on reasonable assumptions, they are subject to numerous factors that could cause actual outcomes and results to be materially different from those indicated in such statements. Such factors include, among others, the inherent uncertainties associated with new projects, changes in business strategy and new lines of business. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Range Impact, Inc.
Investor Relations
P: +1 (216) 304-6556
E: ir@rangeimpact.com
W: www.rangeimpact.com 

Verano to Report Third Quarter 2025 Financial Results on October 29, 2025




Verano to Report Third Quarter 2025 Financial Results on October 29, 2025

CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial results for the third quarter ended September 30, 2025, before the market opens on October 29, 2025.

A conference call and webcast with analysts and investors is scheduled for October 29, 2025 at 8:30 a.m. ET / 7:30 a.m. CT to discuss the results.

• Investors and participants can register in advance for the call by visiting: https://register-conf.media-server.com/register/BI0122898845f54044bfa55206a0105ded
• After registering, instructions will be shared on how to join the call for those who wish to dial in.
• On October 29, the live webcast can be accessed via the following link: https://edge.media-server.com/mmc/p/q42h988w
• The live and archived webcast will be available on the Events and Presentations page of the Company’s investor relations website at investors.verano.com.

About Verano

Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf^™ and MÜV^™ dispensary banners, including Cabbage Club^™, an innovative annual membership program offering exclusive benefits for cannabis consumers. Verano produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano™, (the) Essence^™, MÜV^™, Savvy^™, BITS^™, Encore^™, and Avexia^™. Verano’s active operations span 13 U.S. states, comprised of 15 production facilities with over 1.1 million square feet of cultivation capacity. Learn more at Verano.com.

Contacts:

Media
Verano
Steve Mazeika
Vice President, Communications
Steve.Mazeika@verano.com
312-348-4430

Investors
Verano
Aaron Miles
Chief Investment Officer
Investors@verano.com

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2024 and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

+++

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury




SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

Independent DSMB reports zero device-related safety issues
Supports potential clinical benefit
Trial sample size re-estimated to strengthen statistical power

DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the independent Data Safety Monitoring Review Board (DSMB) has recommended the continuation of the NEUTRALIZE-AKI pivotal trial of the Selective Cytopheretic Device (SCD) therapy in adult patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT).

The interim analysis by the independent DSMB evaluated the safety and potential clinical benefit of the first 100 patients enrolled in the NEUTRALIZE-AKI pivotal clinical trial. The DSMB reported:

• No device-related safety concerns, with zero device-related adverse events. This is consistent with the previously published safety profile of the SCD therapy as well as the preliminary results from the QUELIMMUNE SAVE pediatric registry.
• A signal of potential clinical benefit in the treatment group across key study outcome measures.

To ensure the study is adequately powered to validate the potential clinical efficacy signal, the DSMB recommended increasing the total enrollment from 200 to 339 patients, consistent with the trial’s statistical analysis plan. To date, 137 patients have been enrolled, representing significant progress toward this target. SeaStar Medical is taking proactive steps to accelerate enrollment to meet the new target. It estimates patient enrollment will be complete near the end of 2026, based on the current enrollment rate of clinical trial sites and the addition of several new sites in the NEUTRALIZE-AKI trial.

“We are encouraged by the DSMB’s recommendation, which reinforces the overall safety profile of our SCD therapy and suggests a potential clinical benefit, which we are observing in the commercial setting with QUELIMMUNE in the pediatric population” said Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. “Sample size re-estimations are well established practices in pivotal trials, and while an upward re-estimation will extend the trial timeline, we are optimistic it will strengthen the statistical power and provide critical care teams with greater confidence in the results.”

“Patients continue to face a high risk of death or long-term organ failure due to lack of a disease-modifying therapy, despite availability of CRRT for severe AKI,” said Eric Schlorff, CEO of SeaStar Medical. “The DSMB’s recommendation reinforces our confidence in advancing the NEUTRALIZE-AKI trial and our mission to deliver a first-in-class therapy that can change outcomes for these critically ill patients.”

Mr. Schlorff added, “We intend to continue to drive shareholder value through successful execution of our QUELIMMUNE commercial efforts and the completion of the NEUTRALIZE-AKI trial and the potential filing and approval of the SCD therapy in adult AKI. We have been prudently managing our financial resources and will continue to monitor our options to secure future sources of capital, as needed, to support the achievement of our future milestones.”

The NEUTRALIZE-AKI (NEUTRophil and monocyte deActivation via SeLective Cytopheretic Device – a randomIZEd clinical trial in Acute Kidney Injury) is an event driven study. The trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with the SCD therapy in addition to CRRT as the standard of care, compared with the control group receiving only CRRT standard of care. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90 and dialysis dependency at one year. The study will also include subgroup analyses to explore the effectiveness of the SCD therapy in AKI patients with sepsis and acute respiratory distress syndrome.

SeaStar Medical’s SCD therapy has been approved by the US Food and Drug Administration for use in life-threatening AKI due to sepsis or a septic condition in critically ill pediatric patients. It was approved in 2024 and is sold under the brand name QUELIMMUNE™. It has been adopted by nationally-recognized children’s medical centers throughout the United States. SeaStar Medical recently announced positive preliminary results from the SAVE Surveillance Registry which is assessing the use of the QUELIMMUNE therapy in the commercial setting. Based on the data collected from the first 20 pediatric patients in the SAVE Surveillance Registry, there were no device related safety events with the QUELIMMUNE therapy and 75% of patients survived through 28 days. These data are on track to validate or potentially exceed a 50% reduction in loss of life compared to historical data, as reported in Kidney Medicine.

About Acute Kidney Injury (AKI) and Hyperinflammation

AKI is characterized by a sudden and temporary loss of kidney function and can be caused by a variety of conditions such as sepsis, severe trauma, surgery, and COVID-19. AKI can cause destructive hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from this destructive hyperinflammation in AKI can progress to other organs, such as the heart or liver, and potentially to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, these patients may face complications including chronic kidney disease or end-stage renal disease (ESRD) requiring dialysis. Extreme hyperinflammation may also contribute to added healthcare costs, such as prolonged ICU stays and increased reliance on dialysis and mechanical ventilation.

About the SeaStar Medical Selective Cytopheretic Device Therapy

The SCD therapy is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The SCD therapy is designed for broad applications in multiple acute and chronic kidney and cardiovascular diseases, representing patients who today have no FDA-approved options for treating their disease. Unlike pathogen removal and other blood-purification tools, the SCD therapy is integrated with an existing continuous renal replacement therapy (CRRT) hemofiltration system to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. This unique immunomodulation approach may promote long-term organ recovery, eliminate the need for future CRRT, including dialysis, and prevent loss of life.  

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. It was approved in 2024 by the U.S. Food and Drug Administration (FDA). QUELIMMUNE is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the US annually.

Forward-Looking Statements 

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to anticipated patient benefits from our products including the reduction in loss of life; the potential results of the Save Surveillance Registry study; the expected regulatory approval process and timeline for our products; and the ability of SeaStar Medical to meet the expected timeline. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. 

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Contact:
SeaStar Investor Relations:
IR@SeaStarMed.com

Precision Optics Schedules Fourth Quarter and Fiscal Year 2025 Conference Call for September 29, 2025




Precision Optics Schedules Fourth Quarter and Fiscal Year 2025 Conference Call for September 29, 2025

GARDNER, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) — Precision Optics Corporation, Inc. (Nasdaq: POCI) (the “Company”), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company’s fourth quarter and fiscal year 2025 financial results on Monday, September 29, 2025, at 5:00 p.m. ET.

The Company intends to release its financial results and to file its 10-K after the close of the market on Monday, September 29, 2025, followed by the conference call.

Conference Call Details

Date and Time: Monday, September 29, 2025, at 5:00 p.m. ET.

Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or
(412) 317-5705.

Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/09EyQ6EXoDx.

Replay: A teleconference replay of the call will be available for seven days, at (877) 344-7529 or (412) 317-0088, replay access code 3770234. A webcast replay will be available at https://app.webinar.net/09EyQ6EXoDx.

About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division’s high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.

About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company’s products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company’s filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

Company Contact:
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800

Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
poci@lythampartners.com

uniQure Announces $200 Million Proposed Public Offering




uniQure Announces $200 Million Proposed Public Offering

LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) — uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $200 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to a number of additional ordinary shares equal to 15% of the total number of ordinary shares (and ordinary shares underlying pre-funded warrants) sold in the public offering, on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Leerink Partners, Stifel, Van Lanschot Kempen, and Guggenheim Securities are acting as bookrunning managers for the proposed offering.

The securities described above are being offered by uniQure pursuant to its automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed with the U.S. Securities Exchange Commission (the “SEC”) on January 7, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website at http://www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at +1 (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; Van Lanschot Kempen (USA) Inc., 880 Third Avenue, 17th floor, New York, New York 10022, or by email at equitycapitalmarkets@vanlanschotkempen.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the completion, timing, and size of uniQure’s anticipated public offering, the grant to the underwriters of an option to purchase additional securities, and other statements identified by words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “shall,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict” and similar words or expressions.

Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms, or at all, continued interest in our rare disease portfolio, the ability to develop our product candidates and technologies, the impact of changes in the financial markets and global economic conditions, and other factors described under the heading “Risk Factors” in uniQure’s periodic securities filings with the SEC, including our Annual Report on Form 10-K filed with the SEC on February 27, 2025, our Quarterly Reports on Form 10-Q filed on May 9, 2025 and July 29, 2025, the preliminary prospectus supplement once filed with the SEC and the accompanying prospectus, and other filings that uniQure makes with the SEC from time to time. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and, except as required by law, uniQure assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone




Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

GAITHERSBURG, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) — In recognition of several observances in September meant to keep the national opioid poisoning epidemic front and center, Emergent BioSolutions Inc. (NYSE: EBS) today recommitted to its leadership combating the opioid crisis through a multi-faceted approach focused on awareness, education and widespread access to naloxone, including NARCAN^® Nasal Spray 4 mg and KLOXXADO^® (naloxone HCl) Nasal Spray 8 mg. The observances include:

• National Preparedness Month
• Recovery Month
• Overdose Prevention Week (August 31–September 6)
• National Opioid Awareness Day (September 21)
• National Addiction Professionals Day (September 22)
• Save a Life Day (September 25)
• Trail of Truth (September 27)
• International Recovery Day (September 30)

“As opioid poisonings remain a leading cause of death for Americans, and also a public health crisis in Canada and around the world, it is clear our work is not done,” said Joe Papa, president and CEO of Emergent. “The reality is these deaths are preventable if each of us does our part, and this begins with public awareness and action. We must work together – government, industry, communities, individuals – to eliminate the stigma around naloxone, educate people on where to get it and how to use it, and ensure widespread availability. I am proud of our team at Emergent for helping lead this fight and grateful to our partners across the U.S and Canada for their tireless efforts and advocacy. Even one opioid overdose death is too many.”

Opioid overdose fatalities in the workplace have risen in recent years.¹ Recognizing the continued threat opioid poisonings present, several organizations are taking action, particularly across the business/workplace sector. Emergent has engaged with partners, including the National Safety Council (NSC)*, to educate and reach businesses. Alongside Amazon, Emergent received the Green Cross for Safety Advocate Award at the 2025 NSC Safety Congress Expo for its work to increase access to naloxone in workplaces, including job sites, brick and mortar stores, airlines, hospitality venues and other locations, where emergency response tools such as AED kits are commonplace.

Last week, the National Retail Federation released survey results that show workers in retail settings are very aware of the need for greater access to naloxone, with nearly half (45 percent) saying they have administered or seen naloxone administered themselves. Their bosses recognize the importance of the issue, as well, but remain cautious without broader Good Samaritan protections – a policy Emergent has long supported and will continue to advocate for.

In the same vein, the Penington Institute will develop and publish an International Overdose Awareness Day Global Workplace Engagement Toolkit sponsored by Emergent that is designed to help employers and employees undertake overdose awareness activities and education sessions at work. This new resource will help employees and businesses to start conversations about overdose risks and prevention strategies in their workplaces.

While opioid emergency preparedness is an important component of workplace safety, opioid poisonings can happen to anyone, anywhere, at any time. That is why Emergent is also supporting the SOAR West Virginia Save a Life Day efforts on September 25, 2025, as well as Truth Pharm’s National Trail of Truth event in Washington, D.C. on September 27, 2025, which will serve as a moment of remembrance for families affected by opioid poisoning and a call to action asking government, private industry and public organizations to band together to end this deadly epidemic.

In 2023, NARCAN^® Nasal Spray was the first U.S. Food and Drug Administration approved over-the-counter opioid overdose reversal treatment, marking a significant milestone in making this critical intervention more readily available to the general public. Earlier this year, Emergent gained exclusive commercial rights to distribute KLOXXADO^® (naloxone HCl) Nasal Spray 8 mg, a prescription option for those who choose to administer a higher dose of naloxone. As such, Emergent is the leading U.S. supplier of nasal naloxone and offers an expanded range of products to support public interest groups, workplaces/businesses, as well as patients, consumers and healthcare providers.

• NARCAN^® Nasal Spray 4 mg (two-dose carton)
• NARCAN^® Nasal Spray Wall Unit Kit: includes wall unit cabinet with alarm, poster and wayfinder sign
• KLOXXADO^® Nasal Spray 8 mg (two-dose carton)
• Convenience Kits: includes medical grade components, including one hard case with internal pockets, one medical grade CPR mask, one pair of nitrile examination gloves

Visit NARCANDirect^® or one of Emergent’s product sites, KLOXXADO.com and NARCAN.com to learn how to be prepared in an opioid overdose emergency with life-saving intranasal naloxone.

About NARCAN^® Nasal Spray
NARCAN^® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN^® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.

Indication and Important Safety Information for KLOXXADO^® (naloxone HCl) Nasal Spray 8 mg

What is KLOXXADO^® Nasal Spray?

• KLOXXADO^® Nasal Spray is a prescription medicine used for the treatment of an opioid emergency such as an overdose or a possible opioid overdose in adults and children with signs of breathing problems and severe sleepiness or not being able to respond.
• KLOXXADO^® Nasal Spray is to be given right away and does not take the place of emergency medical care.
• Get emergency medical help right away after giving the first dose of KLOXXADO^® Nasal Spray, even if the person wakes up.

What is the most important information I should know about KLOXXADO^® Nasal Spray?
Get emergency medical help right away after giving the first dose of KLOXXADO^® Nasal Spray. The signs and symptoms of an opioid emergency can return after KLOXXADO^® Nasal Spray is given. If this happens, give another dose after 2 to 3 minutes using a new KLOXXADO^® Nasal Spray and watch the person closely until emergency help is received.

The medicine in KLOXXADO^® Nasal Spray has no effect in people who are not taking opioids. KLOXXADO^® Nasal Spray is not intended for self-administration.

What should I tell my healthcare provider (pharmacist or prescriber) before using KLOXXADO^® Nasal Spray?
Before using KLOXXADO^® Nasal Spray, tell your healthcare provider about all of your medical conditions, including if you:

• have heart problems
• are pregnant or plan to become pregnant. Use of KLOXXADO^® Nasal Spray may cause withdrawal symptoms in your unborn baby. Your unborn baby should be examined by a healthcare provider right away after you use KLOXXADO^® Nasal Spray.
• are breastfeeding or plan to breastfeed. It is not known if KLOXXADO^® Nasal Spray passes into your breast milk.

What are the possible serious side effects of KLOXXADO^® Nasal Spray?
KLOXXADO^® Nasal Spray may cause sudden opioid withdrawal symptoms including body aches, diarrhea, increased heart rate, fever, runny nose, sneezing, goose bumps, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, stomach cramping, weakness, and increased blood pressure.

In infants under 4 weeks old who have been receiving opioids regularly, sudden opioid withdrawal may be life-threatening if not treated the right way. Signs and symptoms include seizures, crying more than usual, and increased reflexes.

Who should not use KLOXXADO^® Nasal Spray?
Do not use KLOXXADO^® Nasal Spray if you are allergic to naloxone hydrochloride or any of the ingredients in KLOXXADO^® Nasal Spray.

What are the most common side effects of KLOXXADO^® nasal spray?
The most common side effects of KLOXXADO^® Nasal Spray in adults include stomach-area (abdomen) pain, weakness, dizziness, headache, nose (nasal) discomfort, and a feeling like you are going to faint.

These are not all of the possible side effects of KLOXXADO^® Nasal Spray. Please see full Prescribing Information, including Patient Information, which includes a more complete discussion of the risks associated with KLOXXADO^® Nasal Spray. Always contact your healthcare provider (pharmacist or prescriber) if you have questions or experience any side effects.

You are encouraged to report negative side effects to the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch. You can also contact Hikma Specialty USA Inc. at: us.hikma@primevigilance.com or call 1-877-845-0689 or 1-800-962-8364.

KLOXXADO^® is a registered trademark of Hikma Pharmaceuticals USA Inc.

About Emergent BioSolutions 
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. 

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

*As a contracted commercial partner of Emergent, NSC will receive a fee for service. 

____________________
¹ National Safety Council Injury Facts Report; https://injuryfacts.nsc.org/work/safety-topics/overdose-deaths/. Accessed September 23, 2025.

Unity Consortium Announces Bold Commitment to Empower Teen Vaccine Ambassadors at Clinton Global Initiative Meeting




Unity Consortium Announces Bold Commitment to Empower Teen Vaccine Ambassadors at Clinton Global Initiative Meeting

Launch of Trusted Teen CommUNITY Program to Reach 12 Million Annually

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) — Unity Consortium today announced the launch of its new Trusted Teen CommUNITY program. This ambitious initiative seeks to educate and mobilize 10,000 Teen CommUNITY Leaders (TCLs) across the country to serve as trusted health ambassadors—sharing lifesaving, science-based health and vaccine information within their communities. The announcement was made as a Clinton Global Initiative (CGI) Commitment to Action at the CGI Annual Meeting in New York. Unity Consortium’s engagement at CGI underscores its unwavering dedication to stopping preventable diseases and building healthier, more resilient communities through youth empowerment and trusted communication.

Responding to Urgent Teen Health Challenges

As adolescents get older, preventive health drops significantly. Many factors contribute to this decline – including being uninsured or underinsured, lack of access to healthcare providers, and difficulty finding reliable vaccine information – all of which lead to lower vaccine rates and leave many teens unprotected. Preventive health visits are an important chance for young people to discuss healthy living behaviors, including vaccination. Less than 70% of adolescents receive annual preventive health visits—well below the Healthy People 2030 target of 83%—and rates are even lower among uninsured or underinsured youth, certain racial and ethnic groups, and youth living in areas with limited access to healthcare.

Only 6 in 10 teens are up to date on the HPV vaccine, and just 18% have completed all recommended meningococcal vaccinations. The HPV vaccine protects against persistent infections that can cause over 90% of cervical, vaginal, vulvar, penile, and anal cancers. Meningococcal disease, though rare, is highly infectious and can result in deadly brain, spinal cord, and bloodstream infections. Without preventive care and vaccination, adolescents face increased risk from diseases that can be stopped before adulthood.

About the Trusted Teen CommUNITY initiative

With inaccurate information spreading and vaccine hesitancy on the rise, credible, science-based education is more critical than ever. The Trusted Teen CommUNITY Initiative gives young leaders the knowledge, resources, and support to share trustworthy, science-based information where it’s needed most. Research shows Americans rely most on their healthcare professionals, family, and close friends for trusted advice. Joined by valued partner Voices for Vaccines, Unity members are joining together to establish a dedicated network of teen leaders who, alongside supportive adult mentors, reclaim the public narrative about their health and the value of vaccines.

The 10,000 Teen CommUNITY Leaders will collectively reach 12 million people each year—bridging divides and sharing information that is meaningful to them and their community.

“We believe in the power of young people to be catalysts for change in their communities. Through the Trusted Teen CommUNITY program, we’re investing in teen leadership and a healthier future for all,” said Judy Klein, President of Unity Consortium. “Our commitment to CGI empowers teens to lead with science, compassion, and courage—building confidence in vaccines where it’s needed most.”

About the Clinton Global Initiative (CGI)

Founded by President Bill Clinton in 2005, the Clinton Global Initiative is a community of doers representing a broad cross section of society and dedicated to the idea that we can accomplish more together than we can apart. Through CGI’s unique model, more than 10,000 organizations have launched more than 4,000 Commitments to Action — new, specific, and measurable projects and programs – that are making a difference in the lives of more than 500 million people in 180 countries.

About Unity Consortium

Unity Consortium is a non-profit organization that brings together diverse stakeholders from both public and private sectors with a common goal of protecting adolescents and young adults from vaccine-preventable diseases to support lifelong health. As the first organization of its kind, Unity convenes immunization experts, public health leaders, healthcare professionals, researchers, advocacy groups, and industry partners to share insights, promote evidence-based collaboration, and shape national strategies for adolescent and young adult immunization. We are action-focused, youth-informed, and committed to making adolescent immunization a top priority. For more information, visit us at https://unity4teenvax.org and follow us on Instagram, LinkedIn, TikTok, and YouTube, and like us on Facebook.

Contact:

Patty Caballero
Unity Consortium
patty@unity4teenvax.org
973.348.5055

Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on a like-for-like basis, mainly due to the decline in activity in France




Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on a like-for-like basis, mainly due to the decline in activity in France

H1 2025 results

Activity and profitability

• H1 revenue: €387.8 million, down 5.4% at CER¹ and on a like-for-like basis², mainly due to the decline in activity in France
• Restated EBITDA margin³ came out at 12.9%, compared with 15.4% a year earlier

2025 financial targets

• Revenue: slight decrease of approximately 1% at CER and on a like-for-like basis
• Restated EBITDA margin: between 12% and 13% of revenue
• Free cash flow: slightly negative

Villepinte, September 24, 2025, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is publishing its consolidated financial statements for the first half of the current year.

Group sales for the period amounted to €387.8 million, down 7.5% compared with the first half of 2024. At constant exchange rates (CER)¹, revenue fell 5.6% on a consolidated basis and 5.4% on a like-for-like basis², with the latter declining less in the second quarter of 2025 (-3.9%) than in the first quarter (-7.1%).

The decline in activity in first-half 2025 mainly stemmed from the contraction in sales in France, as a result of the supply reform implemented on March 1, 2024, which required the Group to adapt its manufacturing chains to the new product mix (the shift from single doses to large bottles). In addition, the Group’s mid-year performance suffered from a demanding basis of comparison, with 11.8% CER growth in first-half 2024.

By geographic region, the revenue of the EMEA region amounted to €169.6 million in the first half of 2025, down 7.7% at CER and like-for-like. Excluding France, revenue grew 6.9% at CER and like-for-like, driven by the increase in volumes.

Sales in the Americas region were stable at CER and like-for-like (-0.3%), reflecting solid volume growth combined with price pressures resulting from the increased weight of distributors in the customer mix.

In Asia, sales came to €98.6 million in the first half of the year, down 7.3% at CER and like-for-like, but the second quarter trended positively, up 1.2%. Performance was impacted by a significant delay in orders.

By business activity, Diagnostic Imaging revenue stood at €334 million at mid-year, down 6.8% at CER and like-for-like.

• The sales of the IRM division (-1.5% at CER and like-for-like) factor in pressure on Dotarem^® prices as well as a solid increase in volumes.
• The decline in X-ray division revenue (-9.7% at CER and like-for-like) primarily resulted from activity in France and South Korea, together with an unfavorable base effect in Latin America.

Interventional Imaging sales totaled €51.9 million in the first half of the year, up 4.6% at CER and like-for-like. They continue to benefit from solid momentum in Lipiodol^® (volumes and prices), particularly in vascular embolization.

* EBITDA = Operating income + net depreciation, amortization and provisions.

The decline in activity and pricing pressures affected profitability over the period, despite tight control of operating costs, in terms of procurement (-6.5%), personnel expenses (-0.5%) and external expenses (-6.1%). EBITDA margin came out at 11.9% in the first half of 2025, compared with 14.6% previously. Restated for exceptional costs related to the optimization of the operational framework and changes in the sales model, the EBITDA margin was 12.9% in first-half 2025.

After depreciation, amortization and provisions totaling €31.1 million (versus €30.7 million a year earlier), operating income was €15.0 million at June 30, 2025.

The Group posted net income of €1.3 million over the period, after accounting for financial expenses, which were down (-11.4%) to €9.9 million, as well as foreign exchange losses for a total of €2.4 million.

Free cash flow negative but improving compared with last year

On the balance sheet, shareholders’ equity stood at €376 million at June 30, 2025, compared with €394 million at end-2024, while net debt stood at €353.3 million (vs. €364.9 million a year ago). Over one year, gearing (net debt/equity ratio) was stable at 0.94.

At mid-year, free cash flow (FCF) was negative (-€8.4 million) but showed a clear improvement compared with first-half 2024 (-€29.1 million). This trend mainly reflects the significant improvement in the working capital requirement.

2025 outlook: adjustment of full-year financial targets

On September 15, Guerbet announced a downward revision of its full-year 2025 financial targets.

The contraction in business activity in France, which continues to be disrupted by supply reform, ongoing pricing pressure, and the unfavorable shift in the customer mix in the United States, with distributors accounting for a higher proportion of sales, as well as a technical issue (now resolved) when restarting operations at the Raleigh site following routine maintenance, are weighing on the Group’s growth and profitability in the current year.

As a result, Guerbet’s management has revised its guidance for full-year 2025 as follows:

• A slight decline in revenue of approximately 1% at constant exchange rates and on a like-for-like basis, compared with growth of between 3% and 5% as previously announced,
• Restated EBITDA margin on revenue of between 12% and 13%, compared with “above 15%” as previously announced,
• Slightly negative free cash flow, compared with the previously announced “positive” level.

Measures have already been taken to safeguard product availability, strengthen sales discipline and optimize the cost base, while strictly monitoring cash generation.

The management is reaffirming its confidence in the Group’s prospects, underpinned by a diversified product portfolio and leading positions in buoyant international markets. The continued ramp-up of Elucirem^TM and accelerated momentum for Lipiodol^® in Interventional Imaging are expected to support a return to growth.

“The results for the first half of 2025 are well below our expectations. To address this situation, we need to act quickly with rigor and determination by focusing all our employees on the following priorities: the recovery of sales in our long-standing businesses; the acceleration of the development of interventional imaging, which continues to trend positively; the rigorous management of our margins and operating costs; and, lastly, the generation of cash necessary to ensure our financial solidity. Jérôme Estampes, appointed Chief Executive Officer of a group that he knows well, has the experience and determination necessary to lead this turnaround in the short term with discipline and method,” said Hugues Lecat, Chairman of the Board of Directors of Guerbet.

Next event:

Publication of Q3 2025 revenue
October 23, 2025, after market close

About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. As pioneers in contrast products for 98 years, with more than 2,905 employees worldwide, we continuously innovate and devote 9% of our revenue to Research and Development in four centers in France and the United States. Guerbet (GBT) is listed in compartment B of Euronext Paris and generated revenue of €841m in 2024. For more information, please visit www.guerbet.com.

Forward-looking statements

Certain information contained in this press release is not historical data but constitutes forward-looking statements. These forward-looking statements are based on estimates, forecasts and assumptions including, without limitation, assumptions regarding the Group’s current and future strategy and the economic environment in which the Group operates. They involve known and unknown risks, uncertainties and other factors, which may result in a significant difference between the Group’s actual performance and results and those presented explicitly or implicitly in these forward-looking statements.

These forward-looking statements are only valid as of the date of this press release and the Group expressly disclaims any obligation or commitment to issue an update or revision of the forward-looking statements contained in this press release to reflect changes in the assumptions, events, conditions or circumstances on which such forward-looking statements are based. Forward-looking statements contained in this press release are for illustrative purposes only. Forward-looking statements and information are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and generally beyond the control of the Group.

These risks and uncertainties include, but are not limited to, uncertainties inherent in research and development, future clinical data and analyses, including post-marketing analyses, decisions by regulatory authorities, such as the Food and Drug Administration or the European Medicines Agency, whether or not to approve, and when, the application for a drug, process or biological product for one of these candidate products, as well as their labeling decisions and other factors that may affect the availability or commercial potential of these candidate products. A detailed description of the risks and uncertainties related to the Group’s activities can be found in chapter 4.8 “Risk factors” of the Group’s Universal Registration Document registered by the AMF under number D.25-0220 on April 3, 2025, available on the Group’s website (www.guerbet.com).

Glossary

Net debt: Net financial debt is defined as the sum of current and non-current borrowings less cash and cash equivalents and marketable securities.

EBITDA: EBITDA is defined as operating income plus net depreciation, amortization, impairment and provisions for risks.

Restated EBITDA: Restated EBITDA is defined as EBITDA minus non-recurring expenses paid to employees following their departure due to restructuring.

Free Cash Flow (FCF): Free cash flow is defined as the change in net debt from one year to the next.

Like-for-like basis: Like-for-like basis refers to the scope excluding the urology and Accurate businesses, sold in July 2024 and January 2025 respectively.

At constant exchange rates: At constant exchange rates means the impact of exchange rates is eliminated by recalculating sales for the period based on the exchange rates used for the previous year.

Consolidated balance sheet

Assets (net values)

Liabilities (net values)

Consolidated income statement

Consolidated cash flow statement

1 At constant exchange rates: the impact of exchange rates was eliminated by recalculating sales for the period based on the exchange rates used for the previous financial year.
2 Excluding the urology and Accurate businesses, which were sold in July 2024 and January 2025 respectively.
3 Excluding non-recurring costs related to the optimization of the operational framework and changes to the sales model.

Attachment

• 2025 09 24 CP GBT RS Vdef 3 EN

EUROBIO SCIENTIFIC: RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025




EUROBIO SCIENTIFIC: RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025

RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025

• Revenue up 10% to €80.7 million
  • Proprietary products account for 36% of revenue
  • 42% of revenue generated outside France
• 2025 results impacted by the transfer of EndoPredict®/Prolaris® production to France
• Free cash flow after investment of €4.4 million
• Net debt of €-2.2 million including EB Development current account

Paris, September 24, 2025 – 5:40 p.m. – Eurobio Scientific (FR0013240934, ALERS, eligible for PEA-PME), a leading French group in in vitro medical diagnostics and life sciences, today presents its consolidated results as of June 30, 2025, prepared in accordance with French standards and approved by the company’s Board of Directors at its meeting on September 23, 2025.

Eurobio Scientific’s results as of June 30, 2025 show growth in activity, an improvement in gross margin linked to the increase in proprietary products, and a decline in EBITDA linked to pressure on distribution margins and transfer costs for EndoPredict®/Prolaris® production from Germany to France in the second quarter of 2025 (approximately €0.8 million).

Growth driven by recent acquisitions and increase in share of proprietary products

Eurobio Scientific posted revenue of €81.2 million in the first half of 2025, compared with €73.5 million in the first half of 2024, representing an increase of €7.7 million (+10.4%). On a comparable basis, i.e. excluding the impact of acquisitions, growth was €4.5 million (+6.1%).

The scope effects are detailed as follows: the inclusion of the EndoPredict® and Prolaris® businesses acquired on August 1, 2024, in the first half of 2025 for €2.7 million, and the acquisition of Quimark, also a distributor of EndoPredict® and Prolaris® in Italy, on March 1, 2025, for €0.5 million.

On a comparable basis, the €4.5 million increase in activity is mainly due to growth in France (+€5.1 million), driven by certain non-recurring factors such as the Chikungunya and Dengue epidemics in overseas territories and the extension for several months of certain tenders in Transplantation, which are maintaining business volumes in this segment for the One Lambda product range. GenDx HLA typing activity remained stable in the first half of 2025 at around €15.6 million. The activities of certain European subsidiaries experienced a slight decline following the discontinuation of the Technoclone distribution ranges in the United Kingdom (-€0.9 million) and T2 Biosystem in Italy (-€1 million).

The share of proprietary products increased from 29% of revenue in the first half of 2024 to 36% in the first half of 2025 due to the inorganic growth policy, but also to the loss of the distribution ranges mentioned above. It amounted to €29.1 million in the first half of 2025 (36% of revenue) compared to €21.2 million (29% of revenue) in the first half of 2024.

Operating income impacted by reorganization costs

The gross margin was 47.4%, up slightly from the first half of 2024 (45.6%) due to the growth in the share of proprietary products in the total revenue mix. Price and margin pressures remain strong for the Distribution business, particularly in the French market.
  
Research and development expenses were stable compared to 2024. The decrease is due to the implementation of more accurate analytical monitoring of the Transplantation business since the beginning of 2025. Marketing and sales expenses increased by €6.1 million, of which €3.5 million was related to the strengthening of the sales and marketing teams at the group and subsidiary levels and €2.6 million was related to scope effects. General and administrative expenses remained stable but included approximately €0.8 million in expenses related to the closure of the production site and the transfer of the EndoPredict® and Prolaris® product lines to France during the first half of 2025.

As a result, EBITDA reached €13.2 million at June 30, 2025, compared with €13.9 million at June 30, 2024. Operating income amounted to €10.3 million, compared with €11.2 million at June 30, 2024, excluding PPA amortization and PPA inventory write-backs.

Financial income was negative at -€2.1 million, mainly due to the servicing of financial debt to EB Development. Extraordinary income was zero due to changes in accounting standards.

Net income thus amounted to €2.4 million at June 30, 2025, compared with €4 million at June 30, 2024.

Free cash flow of €4.4 million

The Group generated a decline in free cash flow to €4.4 million during the first half of the year, mainly due to a change in working capital requirements, which had a negative impact of €5.7 million, and net investment flows of €1.4 million. The transfer of production of the EndoPredict® and Prolaris® ranges from Germany to France had a significant impact on inventories. In addition, the Group saw an increase in average payment terms in certain countries, such as France, for various public and private customers.

At the end of June 2025, Eurobio Scientific had cash and cash equivalents of €26.7 million, financial debt (excluding leases) of €11.3 million, and a current account from EB Development of €17.6 million, resulting in net debt of €2.2 million.

Outlook

Eurobio Scientific has a policy of not communicating its targets for the current financial year. In the medium term, the Eurobio Scientific Group will continue to pursue the strategic priorities it has developed over several years: the development of proprietary products, internationalization, and the opening of new markets. Over the next four years, the Group aims to increase the share of proprietary products to around 50% of its revenue.

Update on Eurobio Scientific shareholding structure

On December 19, 2024, Eurobio Scientific and EB Development announced the final result of the tender offer initiated by EB Development. At the end of this process, after assimilation of the treasury shares held by Eurobio Scientific, EB Development held 9,113,592 shares representing 88.92% of the share capital and theoretical² voting rights of Eurobio Scientific.

On May 19, 2025, EB Development declared that it had individually exceeded the thresholds of 90% of the capital and theoretical voting rights of Eurobio Scientific and that it held, directly and by assimilation of the treasury shares held by Eurobio Scientific, 9,224,652 Eurobio Scientific shares representing the same number of theoretical voting rights, i.e., 90.01% of the capital and theoretical voting rights of the company.

As of June 30, 2025, EB Development holds, directly and by assimilation of the treasury shares held by Eurobio Scientific, 9,227,652 shares representing 90.04% of the share capital and theoretical voting rights of Eurobio Scientific.

Adjusted for (i) the reversal of the inventory value allocated to the PPA at the time of the acquisition of GenDx and sold since then, (ii) amortization of intangible assets arising from the PPA, and (iii) amortization related to goodwill.

² Voting rights calculated in accordance with the provisions of the second paragraph of Article 223-11 I of the AMF General Regulation

Attachment

• CP_Eurobio_Scientific_RS2025_EN